Amgen wins OK on psoriasis drug
- Share via
From Times Wire Services
Amgen Inc. won an advisory panel’s support for the use of its drug Enbrel in children with moderate to severe psoriasis.
The outside experts voted, 8 to 5, to recommend that the Food and Drug Administration expand Enbrel’s approved uses to children with the sometime debilitating skin disorder, after testimony weighing the drug’s benefits against its potential for cancer and other side effects. The FDA isn’t required to follow the panel’s lead, though it usually does.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
